Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Disc Medicine Inc IRON

Healthcare Biotechnology
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond... see more

Recent & Breaking News (NDAQ:IRON)

GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX

Business Wire August 12, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. Merger

Newsfile August 11, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.

PR Newswire August 11, 2022

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ

PR Newswire August 11, 2022

GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders

Business Wire August 10, 2022

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

Business Wire August 10, 2022

Gemini Therapeutics Reports 2021 Financial Results

Business Wire March 10, 2022

Gemini Therapeutics Provides Corporate Update

Business Wire February 28, 2022

Gemini Therapeutics Provides GEM103 Program Update

Business Wire January 10, 2022

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Business Wire November 15, 2021

Gemini Therapeutics Announces Poster Presentation at AAO 2021

Business Wire November 12, 2021

Gemini Therapeutics to Participate in Upcoming Investor Conferences

Business Wire November 11, 2021

Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

Business Wire October 19, 2021

Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 14, 2021

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

Business Wire October 5, 2021

Lightstone Ventures Raises $375 Million Fund

PR Newswire September 14, 2021

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

Business Wire September 10, 2021

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

Business Wire September 9, 2021

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 7, 2021

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

Business Wire August 30, 2021